The Latest Breaking News from Gilead

South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool against the disease

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, named Gilead Sciences, Inc. (NASDAQ:GILD) as his final trade.

Linda-Gail Bekker, who helped prove the drug Lenacapavir’s effectiveness, tells The Independent that $40 doses bring hope – but aid cuts still risk its rollout

Lenacapavir described as ‘next best thing’ to an HIV vaccine will cost $40 a year for each patient in 120 countries from 2027, funders say

The twice-yearly drug has been hailed as a medical breakthrough that could change the course of the HIV epidemic.

As rate cuts loom and after years of lagging, the biotech sector is showing signs of life, with IBB outpacing the benchmark S&P 500 on the quarter.

The U.S. is purchasing enough doses of a new twice-a-year HIV prevention shot to share with up to 2 million people in poor countries by 2028

Gilead Sciences has significantly outperformed the Nasdaq Composite over the past year, and analysts remain strongly bullish on the stock’s prospects.

The new treatment option comes amid a rise in HIV cases in parts of Europe.

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

This biotech giant has hidden strengths that could unlock long-term upside.